SCHEMBL2893545

SCHEMBL2893545

CN1CCN(c2cccc(CN3CC(c4ccccc4)OC3=O)c2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FADS1 O60427 2/20 0.47
AGXT P21549 1/20 0.44
HSD11B1 P28845 2/20 0.42
SIGMAR1 Q99720 5/20 0.41
TMEM97 Q5BJF2 4/20 0.41
GRM2 Q14416 2/20 0.40
NR1H2 P55055 1/20 0.40
NR1H3 Q13133 1/20 0.40
ADRA2C P18825 2/20 0.39
CACNA2D1 P54289 2/20 0.39
SLC6A2 P23975 1/20 0.39
HTR1A P08908 1/20 0.39
ADRA2A P08913 1/20 0.39
ADRA2B P18089 1/20 0.39
DRD1 P21728 1/20 0.39
HRH2 P25021 1/20 0.39
HTR1B P28222 1/20 0.39
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
HTR1E P28566 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2893548 1.00 FADS1 (0.47) FADS1AGXTHSD11B1SIGMAR1TMEM97
SCHEMBL2900293 0.88 FADS1 (0.47) FADS1AGXTHSD11B1SIGMAR1TMEM97
SCHEMBL2900292 0.88 FADS1 (0.47) FADS1AGXTHSD11B1SIGMAR1TMEM97
SCHEMBL2901466 0.88 FADS1 (0.49) FADS1GRM2
SCHEMBL2901469 0.88 FADS1 (0.49) FADS1GRM2
SCHEMBL2901778 0.84 DRD2 (0.45) FADS1SIGMAR1GRM2HTR1ADRD2
SCHEMBL2901775 0.84 DRD2 (0.45) FADS1SIGMAR1GRM2HTR1ADRD2
SCHEMBL13086360 0.82 KDM4E (0.52) FADS1DRD2
SCHEMBL13086217 0.82 KDM4E (0.45) FADS1HTR1ADRD2
SCHEMBL4325271 0.81 MC4R (0.52) FADS1SIGMAR1GRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090012089-A1 Oxazolidinone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators ASTRAZENECA AB (SE) 2009-01-08 US claimed
US-20070275966-A1 Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators NPS PHARMACEUTICALS, INC. (US) 2007-11-29 US claimed
US-7816354-B2 Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2010-10-19 US disclosed
US-20090012089-A1 Oxazolidinone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators ASTRAZENECA AB (SE) 2009-01-08 US disclosed
US-20070275966-A1 Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators NPS PHARMACEUTICALS, INC. (US) 2007-11-29 US disclosed
WO-2007078523-A2 5-PHENYL-3-BENZYL-0XAZ0LIDIN-2-0NE DERIVATIVES AND RELATED COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS ASTRAZENECA AB (SE) 2007-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275966-A1 Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators GRM1, GRIN1, GRM2 FADS1 4353/4885AGXT 1707/4885HSD11B1 2509/4885
US-20090012089-A1 Oxazolidinone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators GRM1, GRIN1, GRM2 FADS1 4353/4885AGXT 1707/4885HSD11B1 2509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.